| Detected | Trial | Change |
|---|---|---|
| 2026-06-03 | NCT03876769 Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients |
date change Primary completion pushed: 2025-08-20 -> 2027-10-19 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT04094311 | Study of Out of Specification for Tisagenlecleucel | B-cell Acute Lymphoblastic Leukemia | Recruiting |
| NCT05888493 | A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult… | Follicular Lymphoma (FL) | Active, Not Recruiting |
| Phase 2 | |||
| NCT05633615 | Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory… | Diffuse Large B-Cell Lymphoma | Recruiting |
| NCT03642626 | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Acute Lymphoblastic Leukemia | Active, Not Recruiting |
| NCT05460533 | A Second Infusion (Early Reinfusion) of Tisagenlecleucel in Children and Young Adults… | B-cell Acute Lymphoblastic Leukemia | Active, Not Recruiting |
| NCT03876769 | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients | B-Cell Acute Lymphoblastic Leukemia | Active, Not Recruiting |
| Phase 1/2 | |||
| NCT06839976 | CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus | SLE | Recruiting |
| Phase 1 | |||
| NCT06408194 | Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies | Leukemia | Recruiting |